HAO Company Profile and Key Details

Haoxi Health Technology Limited generated EPS of $1.34 over the past year. Five-year average earnings growth is 67.01%.

Haoxi Health Technology Limited has 2.21 million shares outstanding. The public float is 1.69 million shares, elevated short interest at 2.26% of float. This equals 40.23 thousand shares. The short ratio is 1.74 days. Institutional investors hold 1.25% of the float. Insiders own 21.79%.

Short-term trend indicators are mixed aligned (SMA20 -1.56%, SMA50 -2.13%, SMA200 -0.99%). The stock’s 14-day RSI is 47.93 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.4% below its high and over 48.17% above its low. Average 10-day trading volume of 37.52 million shares is significantly above the 3-month average of 4.11 million, indicating heightened recent market interest.

Haoxi Health Technology Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.26. This means the shares are trading below this model’s fair value.

Haoxi Health Technology Limited (NASDAQ:HAO) closed at $0.04 USD, losing -$0.68 (-93.84%) from the previous close of $0.73. The stock is currently mid-range between its 52-week high and low $0.04 and $2.31. With a market capitalization of about $337.64 thousand, Haoxi Health Technology Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.57). Key stats such as the average daily volume over the past year has been around 4.19 million shares, trading with heavier-than-usual volume. Headquartered in Beijing, None, Haoxi Health Technology Limited operates in the Communication Services sector and the Advertising Agencies industry. Led by CEO Lei Xu, the company employs approximately 30 people and listed since January 26, 2024. Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China.

Haoxi Health Technology Limited trades at a P/E ratio of -0.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.01 and a price-to-book ratio of 0.01 suggesting the stock is closer to book value. The P/FCF stands at -0.09, also above market averages.

Our AI price prediction model suggests that Haoxi Health Technology Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 411.11%, with price expected at $0.23 by May 25, 2026, within a range of $0.06 to $0.39 3-Month Outlook: Projected fall of -77.78%, reaching $0.01 by August 07, 2026, with a range of $0.00 to $0.10. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 11, 2027, within a range of $0.00 to $5.79.

Haoxi Health Technology Limited (NASDAQ:HAO) shares are up 45.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Haoxi Health Technology Limited trading at a premium to the broader market with a P/E of -0.07. Our AI forecast model points to short-term strength (411.11% over two weeks), a medium-term fall (-77.78% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.